These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31568056)

  • 1. Apparent therapy-resistant hypertension as risk factor for the development of type 2 diabetes mellitus.
    Holtrop J; Spiering W; Nathoe HM; De Borst GJ; Kappelle LJ; De Valk HW; Visseren FLJ; Westerink J;
    J Hypertens; 2020 Jan; 38(1):45-51. PubMed ID: 31568056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.
    Egan BM; Zhao Y; Li J; Brzezinski WA; Todoran TM; Brook RD; Calhoun DA
    Hypertension; 2013 Oct; 62(4):691-7. PubMed ID: 23918752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Muntner P; Davis BR; Cushman WC; Bangalore S; Calhoun DA; Pressel SL; Black HR; Kostis JB; Probstfield JL; Whelton PK; Rahman M;
    Hypertension; 2014 Nov; 64(5):1012-21. PubMed ID: 25259745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES).
    Kaczmarski KR; Sozio SM; Chen J; Sang Y; Shafi T
    BMC Nephrol; 2019 Apr; 20(1):138. PubMed ID: 31023262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistant Hypertension, Time-Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus.
    Viazzi F; Piscitelli P; Ceriello A; Fioretto P; Giorda C; Guida P; Russo G; De Cosmo S; Pontremoli R;
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28939716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Health and Transition From Controlled Blood Pressure to Apparent Treatment Resistant Hypertension: The Jackson Heart Study and the REGARDS Study.
    Akinyelure OP; Sakhuja S; Colvin CL; Clark D; Jaeger BC; Hardy ST; Howard G; Cohen LP; Irvin MR; Tanner R; Carey RM; Muntner P
    Hypertension; 2020 Dec; 76(6):1953-1961. PubMed ID: 33131312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE Study.
    Smith SM; Huo T; Delia Johnson B; Bittner V; Kelsey SF; Vido Thompson D; Noel Bairey Merz C; Pepine CJ; Cooper-Dehoff RM
    J Am Heart Assoc; 2014 Feb; 3(1):e000660. PubMed ID: 24584740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and clinical characteristics of apparent therapy-resistant hypertension in patients with cardiovascular disease: a cross-sectional cohort study in secondary care.
    de Beus E; van der Sande NGC; Bots ML; Spiering W; Voskuil M; Visseren FLJ; Blankestijn PJ
    BMJ Open; 2017 Sep; 7(9):e016692. PubMed ID: 28882918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Apparent Treatment-Resistant Hypertension in the United States.
    Carey RM; Sakhuja S; Calhoun DA; Whelton PK; Muntner P
    Hypertension; 2019 Feb; 73(2):424-431. PubMed ID: 30580690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Apparent Therapy-Resistant Hypertension and Its Effect on Outcome in Patients With Chronic Kidney Disease.
    de Beus E; Bots ML; van Zuilen AD; Wetzels JF; Blankestijn PJ;
    Hypertension; 2015 Nov; 66(5):998-1005. PubMed ID: 26351024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive Blood Pressure Lowering in Patients With and Patients Without Type 2 Diabetes: A Pooled Analysis From Two Randomized Trials.
    Brouwer TF; Vehmeijer JT; Kalkman DN; Berger WR; van den Born BH; Peters RJ; Knops RE
    Diabetes Care; 2018 Jun; 41(6):1142-1148. PubMed ID: 29212825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apparent treatment resistant hypertension and the risk of recurrent cardiovascular events and mortality in patients with established vascular disease.
    Groenland EH; Bots ML; Asselbergs FW; de Borst GJ; Kappelle LJ; Visseren FLJ; Spiering W;
    Int J Cardiol; 2021 Jul; 334():135-141. PubMed ID: 33932429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of developing type 2 diabetes according to blood pressure levels and presence or absence of hypertensive treatment: the Saku study.
    Tatsumi Y; Morimoto A; Asayama K; Sonoda N; Miyamatsu N; Ohno Y; Miyamoto Y; Izawa S; Ohkubo T
    Hypertens Res; 2019 Jan; 42(1):105-113. PubMed ID: 30393378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2017 May; 35(5):922-944. PubMed ID: 28141660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health care fragmentation and blood pressure control among adults taking antihypertensive medication.
    Colvin CL; Safford MM; Muntner P; Colantonio LD; Kern LM
    Am J Manag Care; 2022 Mar; 28(3):108-115. PubMed ID: 35404546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of cardiovascular and renal risk among patients with apparent treatment-resistant hypertension in the United States using machine learning methods.
    Bakris G; Lin PP; Xu C; Chen C; Ashton V; Singhal M
    J Clin Hypertens (Greenwich); 2024 May; 26(5):500-513. PubMed ID: 38523465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apparent resistant hypertension and the risk of vascular events and mortality in patients with manifest vascular disease.
    van der Sande NGC; de Beus E; Bots ML; Voskuil M; Blankestijn PJ; Visseren F; Spiering W;
    J Hypertens; 2018 Jan; 36(1):143-150. PubMed ID: 28763342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality.
    Irvin MR; Booth JN; Shimbo D; Lackland DT; Oparil S; Howard G; Safford MM; Muntner P; Calhoun DA
    J Am Soc Hypertens; 2014 Jun; 8(6):405-13. PubMed ID: 24952653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008.
    Egan BM; Zhao Y; Axon RN; Brzezinski WA; Ferdinand KC
    Circulation; 2011 Aug; 124(9):1046-58. PubMed ID: 21824920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and characteristics of apparent treatment-resistant hypertension in older people in China: a cross-sectional study.
    Wu C; Wang Y; Zhang W; Li X; Wang L; Hui R
    Clin Exp Hypertens; 2019; 41(8):753-758. PubMed ID: 30512984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.